Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Immune profiling of COVID-19 vaccine responses in people with multiple sclerosis on B cell-depleting therapy

View ORCID ProfileGriffith B. Perkins, Christopher M. Hope, Cheng Sheng Chai, Matthew J. Tunbridge, Sebastian Sterling, Kevin Webb, Joey Yap, Arthur Eng Lip Yeow, Makutiro G. Masavuli, Svjetlana Kireta, James D. Zuiani, Anouschka Akerman, Anupriya Aggarwal, Vanessa Milogiannakis, Matthew B. Roberts, William Wilson, Plinio R. Hurtado, Stuart Turville, Branka Grubor-Bauk, Simon C. Barry, P. Toby Coates, Janakan Ravindran, Pravin Hissaria
doi: https://doi.org/10.1101/2023.12.04.23299409
Griffith B. Perkins
1Central and Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital; Adelaide, Australia 5000
2Adelaide Medical School, University of Adelaide; Adelaide, Australia 5000
3Immunology Directorate, SA Pathology; Adelaide, Australia 5000
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Griffith B. Perkins
  • For correspondence: griffith.perkins{at}adelaide.edu.au
Christopher M. Hope
2Adelaide Medical School, University of Adelaide; Adelaide, Australia 5000
4Molecular Immunology, Robinson Research Institute, University of Adelaide; Adelaide, Australia 5000
5Department of Paediatric Medicine, Women’s and Children’s Hospital; North Adelaide, Australia 5000
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cheng Sheng Chai
2Adelaide Medical School, University of Adelaide; Adelaide, Australia 5000
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew J. Tunbridge
1Central and Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital; Adelaide, Australia 5000
2Adelaide Medical School, University of Adelaide; Adelaide, Australia 5000
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sebastian Sterling
2Adelaide Medical School, University of Adelaide; Adelaide, Australia 5000
6Central Adelaide Local Health Network; Adelaide, Australia 5000
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kevin Webb
7Department of Neurology, Royal Adelaide Hospital; Adelaide, Australia 5000
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joey Yap
6Central Adelaide Local Health Network; Adelaide, Australia 5000
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arthur Eng Lip Yeow
2Adelaide Medical School, University of Adelaide; Adelaide, Australia 5000
8Viral Immunology Group, Basil Hetzel Institute for Translational Health Research, University of Adelaide; Woodville, Australia 5011
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Makutiro G. Masavuli
2Adelaide Medical School, University of Adelaide; Adelaide, Australia 5000
8Viral Immunology Group, Basil Hetzel Institute for Translational Health Research, University of Adelaide; Woodville, Australia 5011
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Svjetlana Kireta
1Central and Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital; Adelaide, Australia 5000
2Adelaide Medical School, University of Adelaide; Adelaide, Australia 5000
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James D. Zuiani
2Adelaide Medical School, University of Adelaide; Adelaide, Australia 5000
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anouschka Akerman
9Kirby Institute, University of New South Wales; Sydney, Australia 2052
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anupriya Aggarwal
9Kirby Institute, University of New South Wales; Sydney, Australia 2052
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vanessa Milogiannakis
9Kirby Institute, University of New South Wales; Sydney, Australia 2052
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew B. Roberts
10Infectious Diseases, Royal Adelaide Hospital; Adelaide, Australia 5000
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William Wilson
11Northern Adelaide Local Health Network; Elizabeth Vale, Australia 5112
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Plinio R. Hurtado
1Central and Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital; Adelaide, Australia 5000
2Adelaide Medical School, University of Adelaide; Adelaide, Australia 5000
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stuart Turville
9Kirby Institute, University of New South Wales; Sydney, Australia 2052
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Branka Grubor-Bauk
2Adelaide Medical School, University of Adelaide; Adelaide, Australia 5000
8Viral Immunology Group, Basil Hetzel Institute for Translational Health Research, University of Adelaide; Woodville, Australia 5011
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Simon C. Barry
2Adelaide Medical School, University of Adelaide; Adelaide, Australia 5000
4Molecular Immunology, Robinson Research Institute, University of Adelaide; Adelaide, Australia 5000
5Department of Paediatric Medicine, Women’s and Children’s Hospital; North Adelaide, Australia 5000
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P. Toby Coates
1Central and Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital; Adelaide, Australia 5000
2Adelaide Medical School, University of Adelaide; Adelaide, Australia 5000
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Janakan Ravindran
7Department of Neurology, Royal Adelaide Hospital; Adelaide, Australia 5000
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pravin Hissaria
2Adelaide Medical School, University of Adelaide; Adelaide, Australia 5000
3Immunology Directorate, SA Pathology; Adelaide, Australia 5000
12Department of Immunology, Royal Adelaide Hospital; Adelaide, Australia 5000
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background and Objective People with multiple sclerosis (pwMS) receiving B cell-depleting therapies have impaired antibody responses to vaccination. In a proportion of individuals, repeat vaccination against COVID-19 leads to seroconversion. We sought to describe the immune phenotype of pwMS on ocrelizumab, and identify clinical and immunological determinants of an effective vaccine response.

Methods This was a single-centre, prospective cohort study. Peripheral blood samples were collected from pwMS receiving ocrelizumab (n = 38) pre and post administration of a third dose of mRNA COVID-19 vaccine. Immunogenicity was measured by T cell IFNγ ELISpot, antibody titres, and live virus neutralisation. Humoral immunity was benchmarked against pwMS receiving natalizumab (n = 15), and against a correlate of real-world protection (50% reduction in incidence of infection) from SARS-CoV-2 ancestral and omicron BA.5 variants. The peripheral immune phenotype was comprehensively assessed by flow cytometry, and potential clinical and phenotypic determinants of response to vaccination identified.

Results Immune cell populations relevant to disease and vaccine response were altered in pwMS receiving ocrelizumab versus natalizumab treatment, including depleted CD20-expressing B cell, T cell and NK cell populations, and elevated CD27+CD38+ T cell and ‘NK8’ cell frequencies. Following a third vaccine dose, 51% of pwMS on ocrelizumab were seropositive for SARS-CoV-2 receptor-binding-domain IgG, and 25% and 14% met the threshold for effective neutralisation of live SARS-CoV-2 ancestral and omicron BA.5 virus, respectively. B cell frequency at the time of vaccination, but not time since ocrelizumab infusion, was positively correlated with antibody response, while a strong negative correlation was observed between CD56bright NK cell frequency and antibody response in the ocrelizumab group. In this exploratory cohort, CD3−CD20+ B cells (% of lymphocytes; OR=3.92) and CD56bright NK cells (% of NK cells; OR=0.94) were predictive of an effective neutralising antibody response in second dose non-responders (AUC: 0.98).

Discussion Ocrelizumab treatment was associated with an altered immune phenotype, including recently described T cell and NK populations with potential roles in disease pathogenesis. However, seroconversion was severely impaired by ocrelizumab, and less than half of those who seroconverted following a third vaccine dose demonstrated effective immunity against SARS-CoV-2 ancestral or omicron BA.5. B cell frequency was associated with an effective antibody response, while immunomodulatory CD56bright NK cells were identified as a potential negative determinant of response in those with inadequate B cell numbers. Immune phenotype rather than time since ocrelizumab infusion may help to stratify individuals for prophylaxis.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

ACTRN12623001249640

Funding Statement

This work has received funding from The Hospital Research Foundation Group (outside of structured grant round) and the Health Services Charitable Gifts Board (HSCGB; project grant, 70-05-52-05-20). GBP and MJT received support from the Mary Overton Research Fellowship (HSCGB) and Jacquot Research Scholarship (Royal Australasian College of Physicians), respectively.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was approved by the Central Adelaide Local Health Network Human Research Ethics Committee.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data Availability

Phenotype and correlation data are available as a network (SIF) file, and raw values can be obtained by contacting G.B.P.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted December 05, 2023.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Immune profiling of COVID-19 vaccine responses in people with multiple sclerosis on B cell-depleting therapy
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Immune profiling of COVID-19 vaccine responses in people with multiple sclerosis on B cell-depleting therapy
Griffith B. Perkins, Christopher M. Hope, Cheng Sheng Chai, Matthew J. Tunbridge, Sebastian Sterling, Kevin Webb, Joey Yap, Arthur Eng Lip Yeow, Makutiro G. Masavuli, Svjetlana Kireta, James D. Zuiani, Anouschka Akerman, Anupriya Aggarwal, Vanessa Milogiannakis, Matthew B. Roberts, William Wilson, Plinio R. Hurtado, Stuart Turville, Branka Grubor-Bauk, Simon C. Barry, P. Toby Coates, Janakan Ravindran, Pravin Hissaria
medRxiv 2023.12.04.23299409; doi: https://doi.org/10.1101/2023.12.04.23299409
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Immune profiling of COVID-19 vaccine responses in people with multiple sclerosis on B cell-depleting therapy
Griffith B. Perkins, Christopher M. Hope, Cheng Sheng Chai, Matthew J. Tunbridge, Sebastian Sterling, Kevin Webb, Joey Yap, Arthur Eng Lip Yeow, Makutiro G. Masavuli, Svjetlana Kireta, James D. Zuiani, Anouschka Akerman, Anupriya Aggarwal, Vanessa Milogiannakis, Matthew B. Roberts, William Wilson, Plinio R. Hurtado, Stuart Turville, Branka Grubor-Bauk, Simon C. Barry, P. Toby Coates, Janakan Ravindran, Pravin Hissaria
medRxiv 2023.12.04.23299409; doi: https://doi.org/10.1101/2023.12.04.23299409

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Neurology
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)